Qube Research & Technologies (QRT)’s Aldeyra Therapeutics ALDX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$147K	Buy	87,078 +2,150	+3%	+$9.42K	﹤0.01%	3011
2025 Q4	$440K	Buy	+84,928	New	+$436K	﹤0.01%	2840
2024 Q1	–	Sell	-15,629	Closed	-$54.9K	–	4429
2023 Q4	$54.9K	Buy	+15,629	New	+$48.2K	﹤0.01%	3287
2023 Q2	–	Sell	-78,556	Closed	-$780K	–	2355
2023 Q1	$780K	Buy	78,556 +21,737	+38%	+$154K	﹤0.01%	1392
2022 Q4	$395K	Buy	56,819 +21,091	+59%	+$121K	﹤0.01%	1560
2022 Q3	$191K	Buy	35,728 +16,313	+84%	+$97.9K	﹤0.01%	1785
2022 Q2	$77K	Buy	+19,415	New	+$66.8K	﹤0.01%	2023
2021 Q4	–	Sell	-43,459	Closed	-$382K	–	2488
2021 Q3	$382K	Sell	43,459 -5,039	-10%	-$46.2K	﹤0.01%	1365
2021 Q2	$549K	Sell	48,498 -9,004	-16%	-$108K	0.01%	1246
2021 Q1	$683K	Sell	57,502 -94,687	-62%	-$1.09M	0.01%	1009
2020 Q4	$1.04M	Buy	152,189 +108,303	+247%	+$760K	0.01%	860
2020 Q3	$325K	Buy	43,886 +23,256	+113%	+$150K	﹤0.01%	1205
2020 Q2	$86K	Buy	+20,630	New	+$75.4K	﹤0.01%	1535

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ALDX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Aldeyra Therapeutics (ALDX) stake by 2.5% in Q1 2026, buying an estimated $9.42K and bringing the position to 87,078 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #3011.

Qube Research & Technologies (QRT) first reported a position in ALDX in Q2 2020 and has held it in 13 quarters since. The position peaked at $1.04M in Q4 2020. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Qube Research & Technologies (QRT) held 87,078 shares of Aldeyra Therapeutics worth $147K as of Q1 2026.
Qube Research & Technologies (QRT) bought 2,150 Aldeyra Therapeutics shares in Q1 2026, an estimated $9.42K.
Aldeyra Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3011 holding.
Qube Research & Technologies (QRT) first reported a position in Aldeyra Therapeutics in Q2 2020 and has held it in 13 quarters since.
Qube Research & Technologies (QRT)'s Aldeyra Therapeutics position peaked at $1.04M in Q4 2020.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.